Dyadic International

Company DYAI

Last mentioned: Mar 26, 2026

Timeline

  1. Paysign 2026 Outlook

    Paysign projects 30-35% revenue growth for the coming fiscal year.

  2. Recombinant Albumin Launch

    Dyadic and ProLiant initiate commercial launch of recombinant albumin.

  3. Dyadic Year-End Cash

    Dyadic ends fiscal year with $8.6 million in cash and liquid assets.

  4. Precigen Commercial Launch

    Initial commercial shipments of Papzimius for adult RRP begin.

Stories mentioning Dyadic International 1

market-trends Bullish

Biotech Commercialization Pivot: Dyadic and Precigen Scale Post-R&D

The Q4 2025 earnings cycle marks a critical transition for mid-cap biotech and health-IT firms as they shift from R&D-heavy profiles to commercial-stage entities. Key players like Dyadic and Precigen are reporting initial product revenues and expanded distribution networks, while service providers like Paysign see massive growth in patient affordability programs.

5 sources